"Microdosing" Testosterone Isn't a Clinical Term — Here's What People Actually Mean

"Microdosing" has no established clinical definition in testosterone therapy. It does not appear as a treatment concept in the Endocrine Society guideline, which frames dosing around a target — testosterone concentrations in the mid-normal range — rather than around a schedule.[1] Searched in the medical literature, the term turns up mostly in anti-doping detection research, where it describes small repeated doses used to evade testing. That is a different subject entirely.

None of which makes the underlying idea empty. It just means the word is doing work the evidence has not assigned to it.

What people mean when they say it

In practice the term is used for giving a smaller amount more often instead of a larger amount less often — daily or near-daily administration rather than a weekly or biweekly injection. The total weekly amount may be similar; what changes is how it is divided.

So the substantive question is not "is microdosing better?" It is: does dose frequency matter, and to what?

Where the evidence actually is

The honest state of things:

On dose. This is well characterised. A dose-response study across five weekly doses found fat-free mass, strength, hemoglobin and IGF-I rose with concentration while HDL cholesterol fell — and sexual function, mood and cognition did not change significantly at any dose.[2] Different processes have different dose-response relationships.

On frequency, specifically. Much thinner. There is no equivalent landmark trial randomising men to the same weekly total delivered daily versus weekly and measuring outcomes that matter to patients. Claims that one schedule produces better symptom control than another are, at present, largely extrapolation from pharmacokinetics rather than findings from outcome trials.

On formulation. The most-cited review of testosterone's time-course notes that the variation it documents is "probably related to pharmacodynamics of the testosterone preparation" — an explicit acknowledgement that how a drug is delivered shapes its effect profile, without quantifying the comparison.[3]

Why the idea persists anyway

Because the pharmacokinetic reasoning is intuitive and the lived experience is widely reported. Men on longer-interval injections frequently describe feeling different at different points in the cycle. That is a real report, and the dose-response data give it a plausible mechanism: if effects track concentration, and concentration varies across the interval, effects may vary too.

What does not follow automatically is that any particular schedule fixes it, or by how much. The dosing-interval argument is covered in more detail in daily vs weekly dosing.

What the guideline does say about choosing

The guideline suggests aiming at mid-normal concentrations with any of the approved formulations, taking into account patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden and cost.[1]

That is a genuinely useful framing, and it puts pharmacokinetics on the list without ranking the options. Treatment burden and preference are on the same list — a schedule you will actually follow is not a lesser consideration, since compliance is one of the four things the guideline asks clinicians to monitor.[1]

Frequently asked questions

Is microdosing testosterone safer? There is no trial evidence establishing that. The risks that need monitoring — hematocrit above all — are driven substantially by dose and by individual factors, and the published guidance on erythrocytosis frames both dosage and modality as things to choose with the patient in mind.[4]

Does daily dosing mean I take less overall? Not necessarily. The term describes how the amount is divided, not the total. Your total is set by your target, and the target is mid-normal.[1]

Why does the term show up so much in marketing? Because it describes a real difference in how products are administered, and it sounds precise. Treat it as a description of a schedule rather than as a claim about outcomes, and it stops being misleading.

Should I ask my clinician about dose frequency? Yes — it is explicitly on the guideline's list of things to weigh, alongside your preference and the treatment burden.[1] Just frame it as a fit question rather than as a search for a superior protocol.

The useful version of the question

Not "should I microdose?" but "given my target, my risk factors and what I will realistically stick to, what schedule and formulation fit?" That question has an answer. The other one mostly has vocabulary.

Keen connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, treatment is Keen Testosterone Spray Rx — a once-daily topical spray powered by Hypospray® transdermal delivery.

Related reading: daily vs weekly dosing and what higher doses buy you.

References

4 sources

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
2. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181. doi:10.1152/ajpendo.2001.281.6.E1172 · PMID 11701431
3. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685. doi:10.1530/EJE-11-0221 · PMID 21753068
4. Agrawal P, Singh SM, Kohn T. Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide. Eur Urol Focus. 2023;9(1):20–21. doi:10.1016/j.euf.2022.10.008 · PMID 36335038